Last reviewed · How we verify

NCT00798174

The Effect of an Azygos Vein Coil on Defibrillation Threshold

Completed NA Results posted Last updated 28 September 2018
What this trial tests

NA trial testing Standard configuration vs. azygos coil in Heart Failure in 32 participants. Completed in 18 November 2009.

Timeline
15 December 2008
Primary endpoint
18 November 2009
18 November 2009

Quick facts

Lead sponsorWashington University School of Medicine
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment32
Start date15 December 2008
Primary completion18 November 2009
Estimated completion18 November 2009
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Washington University School of Medicine

Who can join

18 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Difference in the DFT With an Azygos Vein Coil Versus the Standard SVC Coil. Primary · During the course of the implant procedure and testing

Defibrillation threshold will be estimated by repeat defibrillation testing using an azygos coil and using an SVC coil (and compared). The outcome measure quoted below is the mean DFT using the azygos coil vs. the mean DFT using the standard configuration.

DFT wtih Azygos coil
GroupValue95% CI
Standard Configuration vs. Azygos Coil10.4± 7.7
DFT with Standard Configuration
GroupValue95% CI
Standard Configuration vs. Azygos Coil12.2± 8.61

Adverse events — posted to ClinicalTrials.gov

Time frame: 24 hours. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Standard Configuration vs. Azygos Coil Configuation
Serious: 0/25 (0%)
Deaths: 0/25
Other adverse events (1 terms — click to expand)

ReactionSystemStandard Configuration vs.…
Loss of intergrity of Lead introducerBlood and lymphatic system disorders

Data from ClinicalTrials.gov NCT00798174 adverse events section.

Sponsor's own description

When implantable cardiac defibrillators are implanted (ICDs), the defibrillation threshold (DFT), of the amount of energy required to effectively terminate life-threatening arrhythmias is determined. The device is then programmed to discharge a larger amount of energy in order to provide a safety margin. In some patients, the DFT is so high, that an adequate safety margin is not programmable. Placement of a defibrillation lead in the azygos vein has been found to be helpful in these patients. This goal of this trial is to attempt to quantify the average reduction in the DFT (if any) that results from the addition of the azygos lead.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

Other Washington University School of Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00798174.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing